Dilly Stephen George Buys Shares of Codexis, Inc.
Insider Dilly Stephen George purchased 66,350 shares of Codexis, Inc. on June 17, 2026.
Key Points
- Dilly Stephen George bought 66,350 shares of Codexis, Inc. on June 17, 2026, with shares trading at $2.48.
- Codexis, Inc. has a market cap of approximately $233.6 million, with a 52-week range between $0.96 and $3.87.
- Cantor Fitzgerald reiterated its buy rating for Codexis with a target price of $11.00.
Dilly Stephen George, an insider at Codexis, Inc. (NasdaqGS: CDXS), purchased 66,350 shares on June 17, 2026. The shares were acquired at a trading price of $2.48 each, though the transaction's total value was reported as zero, indicating it might have been part of an allocation or award.
Other Institutional Activity in Codexis
Aberdeen Group PLC increased its stake in Codexis by 713,870 shares, now holding 8,680,368 shares valued at about $14.1 million. BlackRock, Inc. trimmed its holdings by 366,967 shares, leaving it with 7,028,773 shares worth approximately $11.5 million. Opaleye Management Inc. made a slight reduction, selling 4,738 shares to hold 6,785,000 shares valued at roughly $11.1 million. Nantahala Capital Management, LLC added 133,444 shares, bringing its total to 4,123,613 shares valued at around $6.7 million. Millennium Management LLC boosted its position by 862,938 shares, ending with 3,998,130 shares worth about $6.5 million.
Codexis, Inc. Stock Snapshot
Shares of Codexis, Inc. (NasdaqGS: CDXS) traded near $2.48. The company has a market cap of about $233.6 million and a forward P/E ratio of -6.95, reflecting its current unprofitability. Codexis has a beta of 2.478, indicating higher volatility compared to the market. The stock's 52-week range is between $0.96 and $3.87, with a 50-day moving average of $2.569 and a 200-day moving average of $2.0225.
Recent Earnings
Codexis reported revenue of $78.1 million, showing a modest growth of 2.1%. However, the company is currently not profitable, with a net margin of -40.97% and a return on equity of -68.9%. The next earnings release is expected on August 12, 2026.
Insider Buying and Selling at Codexis, Inc.
On June 17, 2026, several insiders, including Dilly Stephen George, purchased 66,350 shares each. These transactions were not part of any pre-planned trading program. Other insiders involved in similar transactions on the same date include Christos Richards, Stewart Parker, David Smith, Rahul Singhvi, and Esther Martinborough.
Analysts Set New Price Targets
On August 29, 2024, Cantor Fitzgerald reiterated its buy rating for Codexis, setting a price target of $11.00. Stifel Nicolaus maintained its buy rating with a target of $5.00 on May 20, 2024. Benchmark Co. also maintained a buy rating with a $9.00 target on May 3, 2024. Overall, the consensus among analysts is a "buy," with an average target price of $6.58 based on six opinions.
About Codexis, Inc.
Codexis, Inc. is a biotechnology company based in Redwood City, California. It specializes in developing technology solutions for the manufacturing of therapeutics, utilizing its proprietary CodeEvolver technology platform to discover and commercialize novel enzymes. The company operates globally, providing solutions across various regions including the United States, Europe, and Asia. Led by CEO Dr. Alison Moore, Codexis employs approximately 146 people.
Bottom Line
Insider activity, like the recent purchase by Dilly Stephen George, often attracts attention from investors tracking management's confidence in their company. Codexis, though currently unprofitable, continues to develop its technological platforms in the biotechnology sector. As always, remember that such filings are historical and may not reflect the current state of the company's financials or insider positions.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.